[Skip to Content]
[Skip to Content Landing]
Sept 23, 1968

Procarbazine Therapy for Hodgkin's Disease in Early Pregnancy

Author Affiliations

From the Laboratory of Chemical Pharmacology (Dr. Wells), the surgery (Dr. Marshall), and medicine (Dr. Carbone) branches, National Cancer Institute, Bethesda, Md. Dr. Wells is now at University Hospital, Ann Arbor, Mich.

JAMA. 1968;205(13):935-937. doi:10.1001/jama.1968.03140390059020

Procarbazine hydrochloride, an antineoplastic agent, a teratogen, and a carcinogen, was given to a patient with Hodgkin's disease during the first 5 1/2 weeks of her pregnancy, and a normal infant was delivered. Based on past experience with chemotherapeutic agents given to pregnant women with Hodgkin's disease, the authors present a program of management for the pregnant patient with Hodgkin's disease.